233 related articles for article (PubMed ID: 33855861)
21. Comparative Cost-Effectiveness of Hypertension Treatment in Non-Hispanic Blacks and Whites According to 2014 Guidelines: A Modeling Study.
Vasudeva E; Moise N; Huang C; Mason A; Penko J; Goldman L; Coxson PG; Bibbins-Domingo K; Moran AE
Am J Hypertens; 2016 Oct; 29(10):1195-205. PubMed ID: 27172970
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of Antihypertensive Medication: Exploring Race and Sex Differences Using Data From the REasons for Geographic and Racial Differences in Stroke Study.
Tajeu GS; Mennemeyer S; Menachemi N; Weech-Maldonado R; Kilgore M
Med Care; 2017 Jun; 55(6):552-560. PubMed ID: 28333708
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness of Masked Hypertension Screening and Treatment in US Adults With Suspected Masked Hypertension: A Simulation Study.
Green MB; Shimbo D; Schwartz JE; Bress AP; King JB; Muntner P; Sheppard JP; McManus RJ; Kohli-Lynch CN; Zhang Y; Shea S; Moran AE; Bellows BK
Am J Hypertens; 2022 Aug; 35(8):752-762. PubMed ID: 35665802
[TBL] [Abstract][Full Text] [Related]
25. Barbershop Management of Hypertension in the African American Population: Pitfalls and Opportunities for Extension to Other Underserved Communities.
Ebinger J; Blyler CA; Brettler J; Rader F
Curr Cardiol Rep; 2020 Jun; 22(8):64. PubMed ID: 32562103
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness of Initiating Pharmacological Treatment in Stage One Hypertension Based on 10-Year Cardiovascular Disease Risk: A Markov Modeling Study.
Constanti M; Floyd CN; Glover M; Boffa R; Wierzbicki AS; McManus RJ
Hypertension; 2021 Feb; 77(2):682-691. PubMed ID: 33342242
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness of a Comprehensive Approach for Hypertension Control in Low-Income Settings in Argentina: Trial-Based Analysis of the Hypertension Control Program in Argentina.
Augustovski F; Chaparro M; Palacios A; Shi L; Beratarrechea A; Irazola V; Rubinstein A; Mills K; He J; Pichon Riviere A
Value Health; 2018 Dec; 21(12):1357-1364. PubMed ID: 30502778
[TBL] [Abstract][Full Text] [Related]
28. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).
Houle SK; Chuck AW; McAlister FA; Tsuyuki RT
Pharmacotherapy; 2012 Jun; 32(6):527-37. PubMed ID: 22552863
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR).
Penaloza-Ramos MC; Jowett S; Mant J; Schwartz C; Bray EP; Sayeed Haque M; Richard Hobbs FD; Little P; Bryan S; Williams B; McManus RJ
Eur J Prev Cardiol; 2016 Jun; 23(9):902-12. PubMed ID: 26603745
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of a barber-based intervention for improving hypertension control in black men: the BARBER-1 study: a cluster randomized trial.
Victor RG; Ravenell JE; Freeman A; Leonard D; Bhat DG; Shafiq M; Knowles P; Storm JS; Adhikari E; Bibbins-Domingo K; Coxson PG; Pletcher MJ; Hannan P; Haley RW
Arch Intern Med; 2011 Feb; 171(4):342-50. PubMed ID: 20975012
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension in the United States.
Dixon DL; Johnston K; Patterson J; Marra CA; Tsuyuki RT
JAMA Netw Open; 2023 Nov; 6(11):e2341408. PubMed ID: 37921763
[TBL] [Abstract][Full Text] [Related]
32. Incremental costs associated with physician and pharmacist collaboration to improve blood pressure control.
Kulchaitanaroaj P; Brooks JM; Ardery G; Newman D; Carter BL
Pharmacotherapy; 2012 Aug; 32(8):772-80. PubMed ID: 23307525
[TBL] [Abstract][Full Text] [Related]
33. Barbershops as hypertension detection, referral, and follow-up centers for black men.
Hess PL; Reingold JS; Jones J; Fellman MA; Knowles P; Ravenell JE; Kim S; Raju J; Ruger E; Clark S; Okoro C; Ogunji O; Knowles P; Leonard D; Wilson RP; Haley RW; Ferdinand KC; Freeman A; Victor RG
Hypertension; 2007 May; 49(5):1040-6. PubMed ID: 17404187
[TBL] [Abstract][Full Text] [Related]
34. Screening for proteinuria in US adults: a cost-effectiveness analysis.
Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR
JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of a Multicomponent Intervention for Hypertension Control in Low-Income Settings in Argentina.
Zhang Y; Yin L; Mills K; Chen J; He J; Palacios A; Riviere AP; Irazola V; Augustovski F; Shi L
JAMA Netw Open; 2021 Sep; 4(9):e2122559. PubMed ID: 34519769
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of lower targets for blood pressure and low-density lipoprotein cholesterol in diabetes: the Stop Atherosclerosis in Native Diabetics Study (SANDS) .
Wilson C; Huang CC; Shara N; Howard BV; Fleg JL; Henderson JA; Howard WJ; Huentelman H; Lee ET; Mete M; Russell M; Galloway JM; Silverman A; Stylianou M; Umans J; Weir MR; Yeh F; Ratner RE
J Clin Lipidol; 2010; 4(3):165-72. PubMed ID: 20563294
[TBL] [Abstract][Full Text] [Related]
37. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
Boersma C; Carides GW; Atthobari J; Voors AA; Postma MJ
Clin Ther; 2007 May; 29(5):963-971. PubMed ID: 17697915
[TBL] [Abstract][Full Text] [Related]
38. The (cost-)effectiveness of a patient-tailored intervention programme to enhance adherence to antihypertensive medication in community pharmacies: study protocol of a randomised controlled trial.
van der Laan DM; Elders PJ; Boons CC; Bosmans JE; Nijpels G; Hugtenburg JG
Trials; 2017 Jan; 18(1):29. PubMed ID: 28103948
[TBL] [Abstract][Full Text] [Related]
39. Cost effectiveness of an adherence-improving programme in hypertensive patients.
Brunenberg DE; Wetzels GE; Nelemans PJ; Dirksen CD; Severens JL; Stoffers HE; Schouten JS; Prins MH; de Leeuw PW; Joore MA
Pharmacoeconomics; 2007; 25(3):239-51. PubMed ID: 17335309
[TBL] [Abstract][Full Text] [Related]
40. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
